Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine.
The current World Health Organization recommendation for booster vaccination of previously immunized individuals with potential exposure to rabies is two doses of vaccine intramuscularly or intradermally on days 0 and 3. We report responses to two types of postexposure treatment of healthy individuals who had received preexposure rabies vaccination 1 year previously. Group A individuals received four intradermal doses (one-fifth of the diluent volume of vaccine per dose) on day 0, and group B individuals received two intramuscular doses on days 0 and 3. Immunogenicity of the two booster regimens was assessed by titrating the amount of neutralizing antibody (Nab). We found that the booster doses of vaccine produced remarkable responses in all subjects. Nab titers of > or = 0.5 IU/mL (acceptable antibody level for protection against rabies) were detected in all subjects on day 14, and they were shown to be consistently high 1 year after the booster vaccination. We also found that the Nab titers for group A were significantly higher (two- to eightfold) than those for group B on days 5, 14, 150, and 360 after the initial booster vaccination (P < .05). Our study shows that the four-site intradermal booster regimen with use of one-fifth of the diluent volume of cell-culture rabies vaccine on day 0 is associated with a significantly higher antibody response than is the conventional booster regimen for subsequent postexposure rabies treatment of individuals who have received preexposure rabies vaccination with cell-culture rabies vaccine 1 year previously.
Tantawichien
T
T
Department of Medicine, Chulalongkorn University, and the Queen Saovabha Memorial Institute (World Health Organization Collaborating Center for Research in Rabies Pathogenesis and Prevention), the Thai Red Cross Society, Bangkok.
Benjavongkulchai
M
M
Limsuwan
K
K
Khawplod
P
P
Kaewchompoo
W
W
Chomchey
P
P
Sitprija
V
V
D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007271:Injections, Intradermal; D008297:Male; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology* / Q000302:isolation & purification; D014611:Vaccination / Q000379:methods
D000914:Antibodies, Viral; D011819:Rabies Vaccines